Abstract:Introduction and importance: Li-Fraumeni syndrome (LFS) is a rare hereditary disorder caused by mutations in the TP53 gene, leading to a significantly increased risk of developing various cancers at a young age, including breast cancer. Clinical presentation: This case report details the clinical journey of a 21-year-old female diagnosed with Grade 3 invasive ductal carcinoma, which was estrogen receptor low positive and progesterone receptor negative but positive for Her2 (3+) with a high Ki67 proliferation index. Clinical discussion: Genetic testing confirmed a TP53 mutation, establishing the diagnosis of LFS. The patient underwent neoadjuvant chemotherapy with TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab), resulting in a complete clinical response. This was followed by bilateral skin-sparing and nipple-sparing mastectomy with sentinel lymph node biopsy and immediate reconstruction. Postoperative pathology confirmed a complete response to neoadjuvant therapy. The patient's treatment plan includes 12 cycles of trastuzumab and pertuzumab, with regular echocardiograms to monitor cardiac function and fertility preservation strategies involving monthly Lupron injections. Given the association of LFS with a high risk of multiple primary cancers, a rigorous surveillance strategy is essential. The psychological impact of a cancer diagnosis and the burden of living with a hereditary cancer syndrome were significant, necessitating comprehensive psychosocial support. Conclusion: Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.

Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review.

Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant with a TP53 Germline Mutation: A Case Report and Literature Review

Li-Fraumeni syndrome presenting with de novo TP53 mutation, severe phenotype and advanced paternal age: a case report

A Rhabdomyosarcoma Patient from a Li-Fraumeni Syndrome Family: a Case Report and Literature Review

[Li Fraumeni syndrome: a case with multiple primary cancers and presenting a germline p53 mutation].

A Novel Variant in the TP53 Gene Causing Li-Fraumeni Syndrome

A Young Adult Patient with Li-Fraumeni Syndrome-Associated Glioblastoma: Case Discussion and Literature Review

Pediatric inherited cancer predisposition syndromes and TP53 germ-line mutation

Hematologic malignancies in Li–Fraumeni syndrome: A case report

Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia

Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment

Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome

Genetic and Functional Analysis of a Li Fraumeni Syndrome Family in China

Li-Fraumeni Syndrome: A Rare Genetic Disorder

A novel dysfunctional germline P53 mutation identified in a family with Li-Fraumeni syndrome.

Multiple Primary Tumors in a Family with Li-Fraumeni Syndrome with a TP53 Germline Mutation Identified by Next-Generation Sequencing

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Current insights and future directions of Li-Fraumeni syndrome

An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.